Gamma Delta T Cell Cancer Therapy Market Trends Forecast 2028
05. Mai 2022 07:09 ET
|
KuicK Research
Singapore, May 05, 2022 (GLOBE NEWSWIRE) -- “Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028” Report Highlights: Commercialization Market Potential After Market...
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
16. Dezember 2021 07:00 ET
|
IN8bio, Inc
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to...
Gamma Delta T Cell Therapy Market Clinical Trials Outlook 2026
23. April 2021 08:21 ET
|
KuicK Research
DELHI, India, April 23, 2021 (GLOBE NEWSWIRE) -- “Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights: Commercialization Market...
IN8bio Appoints Alan S. Roemer as Chairman
07. Oktober 2020 07:00 ET
|
IN8bio, Inc
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell...
IN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation
17. September 2020 07:00 ET
|
IN8bio, Inc.
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by...
Incysus Therapeutics Announces Name Change to IN8bio, Inc.
24. August 2020 07:00 ET
|
IN8bio, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (γδ) T cell immunotherapies for the...
Incysus Therapeutics to Present at Solebury Trout Private Company Showcase
07. August 2020 08:35 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Incysus Therapeutics to Present at LifeSci Partners Summer Symposium
03. August 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma
02. Juni 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
28. Mai 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...